Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2016

01-10-2016 | Review

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors

Authors: Giuseppe Lo Russo, Sara Pusceddu, Natalie Prinzi, Martina Imbimbo, Claudia Proto, Diego Signorelli, Milena Vitali, Monica Ganzinelli, Marco Maccauro, Roberto Buzzoni, Ettore Seregni, Filippo de Braud, Marina Chiara Garassino

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

Well-differentiated bronchial neuroendocrine tumors (B-NETs) are rare. They represent 1–5 % of all lung cancers. The incidence of these neoplasms has risen over the past 30 years and, especially for advanced or metastatic disease, management is complex and requires a multidisciplinary approach. Treatment with somatostatin analogs (SSAs) is the most important first-line therapy, in particular in well-differentiated NETs with high somatostatin type receptor (SSTR) expression. In these tumors, the role of mammalian target of rapamycin (m-TOR) inhibitors and the potential utility of other target therapies remain unclear while chemotherapy represents the gold standard treatment only for aggressive forms with low SSTR expression. Peptide receptor radionuclide therapy (PRRT) is an emerging treatment modality for advanced NETs. There are many cumulative evidences about the effectiveness and tolerability of this therapeutic approach, especially in gastro-entero-pancreatic (GEP)-NETs. For B-NETs, scientific research is moving more slowly. Here, we performed a review in order to evaluate the efficacy and toxicity of PRRT with a focus on patients with inoperable or metastatic well-differentiated B-NETs.
Literature
1.
Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.CrossRefPubMed
2.
Naalsund A, Rostad H, Strom EH, et al. Carcinoid tumors incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg. 2010;39:565–9.CrossRef
3.
Rekhtman N. Neuroendrine tumors of the lung: an update. Arch Pathol Lab Med. 2010;123:1628–38.
4.
Travis WD, Brambilla E, Muller-Hermelink H, Harris C. Tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
5.
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRefPubMed
6.
Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMed
7.
Lo Russo G, Pusceddu S, Proto C, et al. Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol. 2016;37:7047–57.CrossRefPubMed
8.
Pusceddu S, Lo Russo G, Macerelli M, et al. Diagnosis and management of typical and atypical lung carcinoids. Crit Rev Oncol Hematol. 2016;100:167–76.CrossRefPubMed
9.
Filosso PL, Ferolla P, Guerrera F, et al. Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis. 2015;7:163–71.
10.
Caplin ME, Baudin E, Ferolla P, et al. ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015; pii: mdv041.
11.
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46:62–6.
12.
Krenning EP, Bakker WH, Breeman WA, et al. Localization of endocrine related tumors with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–5.CrossRefPubMed
13.
Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;15:496–506.CrossRef
14.
Anthony LB, Woltering EA, Espanan GD, et al. Indium-111-pentetreotide prolongs survival in gastro entero pancreatic malignancies. Semin Nucl Med. 2002;32:123–32.CrossRefPubMed
15.
Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]-octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110–22.CrossRefPubMed
16.
de Jong M, Bakker WH, Krenning EP, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368–71.PubMed
17.
Otte A, Muller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;7:417–8.CrossRef
18.
Paganelli G, Zoboli S, Cremonesi M, et al. Receptor mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–34.CrossRefPubMed
19.
Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941–5.CrossRefPubMed
20.
Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610–6.PubMed
21.
Bodei L, Cremonesi M, Zoboli S, et al. Receptor mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207–16.CrossRefPubMed
22.
Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1038–46.CrossRefPubMed
23.
Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147–56.CrossRefPubMed
24.
Bushnell Jr DL, O’Dorisio TM, O’Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652–9.CrossRefPubMedPubMedCentral
25.
Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787–94.CrossRefPubMed
26.
Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90YDOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23.CrossRefPubMed
27.
Pfeifer AK, Gregersen T, Gronbaek H, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011;93:189–96.CrossRefPubMed
28.
Bernard BF, Krenning EP, Breeman WA, et al. D-lysine reduction of indium-111octreotide and yttrium-90octreotide renal uptake. J Nucl Med. 1997;38:1929–33.PubMed
29.
Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439–47.CrossRefPubMed
30.
Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552–4.CrossRefPubMed
31.
Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.CrossRefPubMed
32.
Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.CrossRefPubMed
33.
Sward C, Bernhardt P, Ahlman H, et al. [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg. 2010;34:1368–72.CrossRefPubMed
34.
Garkavij M, Nickel M, Sjogreen-Gleisner K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92.CrossRefPubMed
35.
Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I–II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.CrossRefPubMed
36.
Sansovini M, Severi S, Ambrosetti A, et al. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97:347–54.CrossRefPubMed
37.
Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neu-roendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55:183–90.CrossRefPubMed
38.
Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42:1238–46.CrossRefPubMed
39.
Paganelli G, Sansovini M, Ambrosetti A, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41:1845–51.CrossRefPubMed
40.
Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014;43:518–25.CrossRefPubMed
41.
Sabet A, Ezziddin S, Heinemann F, et al. Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy. Nuklear medizin. 2012;51:95–100.CrossRef
42.
Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed
43.
Bodei L, Cremonesi M, Kidd M, et al. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac Surg Clin. 2014;24:333–49.CrossRefPubMed
44.
Sabet A, Biersack HJ, Ezziddin S. Advances in Peptide Receptor Radionuclide Therapy. Semin Nucl Med. 2016; 46:40–6.
45.
Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin N Am. 2016:179–91.
46.
de Jong M, Breeman WA, Valkema R, et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;4:13–7.
47.
Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97.CrossRefPubMedPubMedCentral
48.
Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu- DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30:1100–6.CrossRefPubMed
49.
Seregni E, Maccauro M, Coliva A, et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54:84–91.PubMed
50.
Seregni E, Maccauro M, Chiesa C, et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2014;41:223–30.CrossRefPubMed
51.
Kunikowska J, Królicki L, Sowa-Staszczak A, et al. Polish experience in peptide receptor radionuclide therapy. Recent Results Cancer Res. 2013;194:467–78.CrossRefPubMed
52.
Limouris GS, Chatziioannou A, Kontogeorgakos D, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008;35:1827–37.CrossRefPubMed
53.
McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005;237:718–26.CrossRefPubMed
54.
Pool SE, Kam BL, Koning GA, et al. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy. Cancer Biother Radiopharm. 2014;29:179–87.CrossRefPubMed
55.
Kratochwil C, Lopez-Benitez R, Mier W, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendo-crine liver metastases. Endocr Relat Cancer. 2011;18:595–602.CrossRefPubMed
56.
Nayak TK, Norenberg JP, Anderson TL, et al. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta (−)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol. 2007;34:185–93.CrossRefPubMed
57.
Miederer M, Henriksen G, Alke A, et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res. 2008;14:3555–61.CrossRefPubMed
58.
Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuro-endocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–19.CrossRefPubMedPubMedCentral
59.
Wang X, Fani M, Schulz S, et al. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:1876–85.CrossRefPubMed
60.
Cescato R, Waser B, Fani M, et al. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52:1886–90.CrossRefPubMed
61.
Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248–52.CrossRefPubMed
62.
Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436–41.CrossRefPubMedPubMedCentral
63.
van Essen M, Krenning EP, Kam BL, et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:743–8.CrossRefPubMedPubMedCentral
64.
Claringbold PG, Brayshaw PA, Price RA, et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302–11.CrossRefPubMed
65.
Claringbold PG, Price RA, Turner JH. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced lowgrade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27:561–9.CrossRefPubMed
66.
Claringbold PG, Turner JH. NeuroEndocrine tumor therapy with lutetium-177-octreotate and everolimus (NETTLE): a phase I study. Cancer Biother Radiopharm. 2015;30:261–9.CrossRefPubMed
67.
Kaemmerer D, Prasad V, Daffner W, et al. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol. 2009;15:5867–70.CrossRefPubMedPubMedCentral
68.
Ezziddin S, Lauschke H, Schaefers M, et al. Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin Nucl Med. 2012;37:102–4.CrossRefPubMed
69.
Stoeltzing O, Loss M, Huber E, et al. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbeck's Arch Surg. 2010;395:185–92.CrossRef
70.
Sowa-Staszczak A, Pach D, Chrzan R, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38:1669–74.CrossRefPubMedPubMedCentral
71.
Barber TW, Hofman MS, Thomson BN, et al. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012;38:64–71.CrossRefPubMed
72.
van Vliet EI, van Eijck CH, de Krijger RR, et al. Neoadjuvant treatment of non functioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2015;56:1647–53.CrossRefPubMed
73.
van Essen M, Krenning EP, Kam BL, et al. Salvage therapy with 177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51:383–90.CrossRefPubMed
74.
Sabet A, Haslerud T, Pape UF, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:205–10.CrossRefPubMed
75.
Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of retreatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015;42:1955–63.CrossRefPubMed
76.
Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9–15.CrossRefPubMed
77.
Forrer F, Krenning EP, Kooij PP, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–46.CrossRefPubMedPubMedCentral
78.
Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61.CrossRefPubMed
79.
Marincek N, Jörg AC, Brunner P, et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med. 2013;11:17.CrossRefPubMedPubMedCentral
80.
Romer A, Seiler D, Marincek N, et al. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:214–22.CrossRefPubMed
81.
Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.CrossRefPubMed
82.
Hörsch D, Ezziddin S, Haug A, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up. Eur J Cancer. 2016;58:41–51.CrossRefPubMed
83.
Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23.CrossRefPubMed
84.
Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–10.CrossRefPubMed
85.
Turner NC, Strauss SJ, Sarker D, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer. 2010;102:1106–12.CrossRefPubMedPubMedCentral
86.
Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46:83–91.
87.
Ranade R, Basu S. 177Lu-DOTATATE based PRRT in patients of metastatic neuroendocrine tumor with single functioning kidney: evaluation of tolerability and effect on renal function parameters. J Nucl Med Technol. 2016. pii: jnmt.115.168146.
88.
Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56.CrossRefPubMed
89.
Gupta SK, Singla S, Bal C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm. 2012;27:593–9.CrossRefPubMed
90.
Svensson J, Berg G, Wangberg B, et al. Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment. Eur J Nucl Med Mol Imaging. 2015;42:947–55.CrossRefPubMedPubMedCentral
91.
Strosberg J, Wolin E, Chasen B, et al. 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1 trial. European Cancer Congress 2015. Abstract 6LBA.
92.
Forrer F, Uusijarvi H, Storch D, et al. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90YDOTATOC. J Nucl Med. 2005;46:1310–6.PubMed
93.
Baum RP, Kluge AW, Kulkarni H, et al. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-octreotide ((177)Lu-DOTATOC) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: a phase-II study. Theranostics. 2016;6:501–10.CrossRefPubMedPubMedCentral
94.
Basu S, Ranade R, Thapa P. Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: evaluation of response and hematological toxicity profile of PRRT with (177)Lu-DOTATATE. World J Nucl Med. 2016;15:38–43.PubMedPubMedCentral
95.
Vinjamuri S, Gilbert TM, Banks M, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013;108:1440–8.CrossRefPubMedPubMedCentral
96.
Danthala M, Kallur KG, Prashant GR, et al. (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years’ experience from a tertiary cancer care Centre in India. Eur J Nucl Med Mol Imaging. 2014;41:1319–26.CrossRefPubMed
97.
van Essen M, Krenning EP, Bakker WH, et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34:1219–27.CrossRefPubMed
98.
Ianniello A, Sansovini M, Severi S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2016;43:1040–6.CrossRefPubMed
99.
Mariniello A, Bodei L, Tinelli C, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43:441–52.CrossRefPubMed
100.
van Vliet EI, Hermans JJ, de Ridder MA, et al. Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions. J Nucl Med. 2012;53:1359–66.CrossRefPubMed
101.
van Vliet EI, Krenning EP, Teunissen JJ, et al. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2013;54:1689–96.CrossRefPubMed
102.
Bodei L, Kidd M, Modlin IM, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43:839–51.CrossRefPubMed
103.
Khan S, Krenning EP, van Essen M, et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52:1361–8.CrossRefPubMed
104.
Kim SJ, Pak K, Koo PJ, et al. The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:1964–70.CrossRefPubMed
Metadata
Title
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors
Authors
Giuseppe Lo Russo
Sara Pusceddu
Natalie Prinzi
Martina Imbimbo
Claudia Proto
Diego Signorelli
Milena Vitali
Monica Ganzinelli
Marco Maccauro
Roberto Buzzoni
Ettore Seregni
Filippo de Braud
Marina Chiara Garassino
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5258-9

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue

Original Article

High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer

Original Article

Ganoderic acid targeting multiple receptors in cancer: in silico and in vitro study

Review

Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance

Original Article

Quercetin modulates Wnt signaling components in prostate cancer cell line by inhibiting cell viability, migration, and metastases

Original Article

Identification of aldolase A as a potential diagnostic biomarker for colorectal cancer based on proteomic analysis using formalin-fixed paraffin-embedded tissue

Review

Control of stress signaling in stem cells: crossroads of stem cells and cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits